Navigation Links
Results of Boehringer Ingelheim Oral Hepatitis C Protease Inhibitor and Polymerase Inhibitor Combination Phase Ib Trial Shows Rapid Viral Response Without Use of Pegylated Interferon
Date:10/30/2010

BOSTON and RIDGEFIELD, Conn., Oct. 30, 2010 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc. announced today results from a Phase Ib study, SOUND-C1, that showed the combination of two oral hepatitis C virus (HCV) compounds, the protease inhibitor BI 201335 and the polymerase inhibitor BI 207127, with ribavirin reduced viral load below the lower limit of quantifiable levels in HCV treatment-naive patients. The regimen did not include interferon through the first 28 days of treatment. These data are being presented at the American Association for the Study of Liver Diseases (AASLD) 2010 Liver Meeting in Boston, MA.

(Poster LB-7) New protease-polymerase inhibitor combination resulted in 73-100% rapid virological responses without pegylated interferonIn this randomized open-label trial, 32 treatment-naive genotype-1 HCV patients received BI 207127 in either 400mg or 600mg doses three times a day (TID), BI 201335 120mg once daily (QD) and ribavirin (RBV) (1000/1200mg daily in two doses) for 28 days. All patients had a rapid and sharp decline in HCV viral load during the first two days, followed by a slower second phase decline. In the lower and higher dose groups, 73 and 100% of patients achieved a rapid virological response (i.e. HCV RNA below lower limit of quantification after 4 weeks of treatment). One patient experienced a viral breakthrough (increase by >1 LOG10 from nadir during treatment) and one other experienced a 0.7 LOG10 increase in viral load. Both were in the lower dose group of BI 207127 and were patients with high baseline viral load. On day 29, all patients were switched to treatment with BI 201335 and PegIFN/RBV for an additional 44 weeks per the defined study protocol, and will be followed to evaluate sustained virological response.

"The current standard-of-care, PegIFN/RBV, is challenging for patients with chronic hepatitis C due to significant side effects that impact treatment adherence and has suboptimal response
'/>"/>

SOURCE Boehringer Ingelheim Pharmaceuticals
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
2. Lexicon to Present Research Results at American Chemical Society Meeting Regarding Target of LX1031 Drug Candidate
3. Positive Kuvan(TM) Pivotal Phase 3 Trial Results Published in The Lancet
4. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
5. Tapestry Reports Second Quarter 2007 Results
6. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
7. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
8. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
9. Genta Incorporated Announces Second Quarter 2007 Financial Results and Corporate Highlights
10. Vical Reports Second Quarter 2007 Financial Results, Allowance of Pandemic Influenza IND and Other Advances in Product Development Programs
11. MicroDose Announces Positive Results From the QDose Inhaled Insulin Glucose Clamp Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/4/2015)... 4, 2015 Fair Rate Funding, a lawsuit funding ... reports a dramatic increase in lawsuit filings in connection with ... lawsuits in the Philadelphia Court of ... cases.  In the Louisiana multi---district litigation ... District of Louisiana , the filings are ...
(Date:9/4/2015)... , Sept. 4, 2015  Pharmaceutical companies ... and other Field-Based Medical Specialists (FBMS) to build ... leaders, and thought leaders in critical therapeutic areas. ... their field-based teams, companies are expanding the critical ... align countries with corporate objectives and to achieve ...
(Date:9/4/2015)... -- Dohmen Company CEO Cynthia LaConte is the ... Commerce,s annual ,Future 50, Awards luncheon, to be held ... 50, Awards highlights the achievements of 50 local, fast-growing ... the seven-county Milwaukee region. ... home for more than 150 years, and LaConte ...
Breaking Medicine Technology:Xarelto Lawsuit Funding Firm, Fair Rate Funding Reports a Steady Rise in Xarelto Product Liability Lawsuit Filings 2Xarelto Lawsuit Funding Firm, Fair Rate Funding Reports a Steady Rise in Xarelto Product Liability Lawsuit Filings 3New Study Presents Tactics and Insights on How to Effectively Globalize Medical Science Liaison Programs in the Pharmaceutical Industry 2Dohmen CEO Cynthia LaConte to Keynote MMAC 'Future 50' Awards Luncheon 2
(Date:9/4/2015)... ... ... Mile High Connects today releases “First and Last Mile Connections,” a groundbreaking report ... and other vital supports severely limit access to public transportation for many users. , ... public transit, there’s very little support for safe and convenient access to the transit ...
(Date:9/4/2015)... ... September 04, 2015 , ... The Schmidt National Law Group filed ... Paz. , Schmidt National Law Group, a leading firm in mass-tort litigation, has ... Bayer Corp., Bayer Essure, Inc., and other Bayer affiliates for injuries alleged to have ...
(Date:9/4/2015)... ... 2015 , ... The Providence Fertility Center will host a Fertility Cocktail Hour" ... freezing. , Date and Time: October 8, 2015 at Waterman Grille restaurant and lounge, ... event will discuss the basics of female fertility and egg freezing, and offer women ...
(Date:9/4/2015)... (PRWEB) , ... September 04, 2015 , ... IVF New ... host a New Hampshire fertility "ManchVegas Happy Hour" in Manchester for women who wish ... 15, 2015 at XO on Elm restaurant and lounge, 827 Elm Street, Manchester, NH ...
(Date:9/4/2015)... Bogart, GA (PRWEB) , ... September 04, 2015 ... ... serving Bogart and the surrounding communities, is launching a charity effort to provide ... , Commonly referred to as an enlarged heart, restrictive cardiomyopathy often leads to ...
Breaking Medicine News(10 mins):Health News:Missed Connections in Metro Denver Transit 2Health News:Schmidt National Law Group Files First Bayer Essure® Lawsuit in California 2Health News:The Providence Fertility Center to Host Fertility Cocktail Hour on October 8, 2015 at Waterman Grille for Women Who Wish to Learn About Their Fertility and Egg Freezing 2Health News:IVF New England to Host ManchVegas New Hampshire Fertility Happy Hour on October 15, 2015 in Manchester for Women Who Wish to Learn More About Fertility and Egg Freezing 2Health News:Georgia Insurance Advisors Inaugurates Charity Drive to Assist the Family of Young Local Girl Diagnosed with an Enlarged Heart 2Health News:Georgia Insurance Advisors Inaugurates Charity Drive to Assist the Family of Young Local Girl Diagnosed with an Enlarged Heart 3
... led by a,team of education researchers from Mayo ... the American Medical Association (JAMA) concludes that,Internet-based education ... M.D., an associate professor of medicine who,practices general ... Mayo and McMaster University in Hamilton, Ontario. They ...
... MedImmune, the,global biologics unit of AstraZeneca, and ... Inc., announced today that they have entered,into a ... Biotech,s anti-ILT7 protein for the potential treatment of ... has,global rights to any resulting product candidates and ...
... During Hispanic Heritage Month Work to ... Population, ALEXANDRIA, Va., Sept. 11 To celebrate ... those in the,Hispanic/Latino American population who have, or are ... grant from the Abbott Fund, is,introducing its new Adult ...
... current outbreaks of listeriosis in Canada connected to ... releasing guidelines for health care professionals and the ... symptom management, and how to reduce the risk ... United States, about 20-65% of all foodborne-related deaths ...
... making waiting room time more enjoyable and informative for ... country and helping doctors become more profitable in the ... network is Ear, Nose & Throat Associates of South ... this month in Chicago at AOA-26 and OTO EXPO ...
... Texas, Sept. 11 Wound Management,Technologies, Inc., (OTC Bulletin ... of the year and for 2009. "The company,has been ... market for,the first 3 quarters of the year to ... in the world. We have been working,with several major ...
Cached Medicine News:Health News:Mayo Clinic, McMaster University Research Review Shows Internet-based Instruction Effective for Teaching Health Care Professionals 2Health News:MedImmune Further Expands Autoimmune Disease Research Program Through Collaboration with SBI Biotech 2Health News:American Diabetes Association Announces New Latino Diabetes Toolkit 2Health News:American Diabetes Association Announces New Latino Diabetes Toolkit 3Health News:Mediplay Makes Marketing More Profitable For Physicians 2Health News:Mediplay Makes Marketing More Profitable For Physicians 3Health News:Wound Management Technologies, Inc. Announces Strategic Plans for Revenue Growth for Year End and 2009 2
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: